Celcuity Announces First Patient Dosed in Phase Ib/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer

Celcuity, Inc. announced that the first patient has been dosed in its Phase Ib/II study evaluating gedatolisib in combination with Nubeqa®, an approved androgen receptor inhibitor, for the treatment of patients with metastatic castration resistant prostate cancer.
[Celcuity, Inc. (GlobeNewswire, Inc.)]
Press Release